Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

Risk Reductions of 46% to 52% for Heart Failure Readmissions and for Composite of CV Death and Heart Failure Readmissions at 30- and 90-Days Following Hospital Discharge

News | Heart Failure

New Analysis of SOLOIST-WHF Results Demonstrates Sotagliflozin’s Significant Effect in Reducing the Risk of Hospital Readmissions for Heart Failure

November 9, 2022 — Lexicon Pharmaceuticals, Inc. announced that a new analysis of results from the SOLOIST-WHF Phase 3 ...

November 09, 2022

News | Hypertension

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part ...

November 09, 2022

New genomic therapies for cardiovascular disease are reaching the clinical trial stage, according to moderators of a session presented at the American Heart Association Annual Scientific Session (AHA2022).

News | AHA

Progress Reported on Clinical Trials of Genomic Profiling for Cardiovascular Disease at AHA 2022

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be ...

November 08, 2022

Robert J. Mentz, M.D., Associate Professor of Medicine, Chief, Heart Failure Section, Associate Program Director, Duke Cardiology Fellowship, Duke University Medical Center, Duke Clinical Research Institute, Durham, North Carolina, image copyright Robert J. Mentz

News | AHA

TRANSFORM-HF Trial Found No Difference in Effectiveness Between 2 Common Loop Diuretics

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication ...

November 08, 2022

Julian D. Gillmore, M.D., Ph.D., Professor, University College London Centre for Amyloidosis, United Kingdom, image copyright University College London Centre for Amyloidosis

News | AHA

Novel Gene-Editing Therapy Shows Promise For Patients With Transthyretin Amyloid Cardiomyopathy

November 8, 2022 — A single IV infusion of NTLA-2001, a novel CRISPR/Cas9-based gene editing therapy, significantly ...

November 08, 2022

Clinical studies presented at the American Heart Association 2022 Scientific Sessions event demonstrate compelling diagnostic and health economic value of the Zio suite of products across a range of clinical applications

News | AHA

Results of Four Studies Demonstrating Clinical, Economic Value of iRhythm’s Product Portfolio Presented at American Heart Association ’22

November 8, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

November 08, 2022

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment

News | AHA

Late-Breaking Data Demonstrate AHA/ACC Guideline-Directed CCTA ± FFRCT Precision Pathway is Superior to Traditional Testing

November 7, 2022 — HeartFlow, Inc., the leader in revolutionizing precision heartcare, today announced new trial results ...

November 07, 2022

A new analysis of iRhythm’s mSToPS trial, presented at the American Heart Association, reveals that Zio XT provided high value from a health economic perspective

News | AHA

New Research Confirms that Zio by iRhythm Provides High Value From a Health Economic Perspective

November 7, 2022 — iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions ...

November 07, 2022

Petr Ostadal, M.D., Ph.D., Professor of Medicine, Department of Cardiology, Na Homolce Hospital, Czech Republic. Image copyright Na Homolce Hospital

News | AHA

Early Use of ECMO devices Did Not Improve Outcomes in People With Cardiogenic Shock

November 7, 2022 — The immediate use of veno-arterial mechanical circulatory extracorporeal membrane oxygenation (ECMO) ...

November 07, 2022

Study Advances Efforts to Launch CARDIALYTICS Suite of Analytic Tools

News | EP Lab

CathVision Announces Initiation of Clinical Study Evaluating Signal Complexity Algorithm

Nov. 4, 2022 — CathVision, a medical technology company developing innovative electrophysiology solutions to enhance ...

November 05, 2022

Late-breaking clinical presentations at VIVA show IN.PACT Admiral drug-coated PTA balloon catheter outperforms bare metal stents; maintains performance in real-world setting

News | VIVA

Clinical Studies Show Medtronic Drug Coated Balloon Outperforms Bare Metal Stents; Maintains Performance in Real World

November 3, 2022 — Medtronic, a global leader in medical technology, today announced the results of two clinical studies ...

November 03, 2022

A mouse heart with immune infiltrates leading to ICI-myocarditis. Image courtesy of UCSF

News | Coronavirus (COVID-19)

Study Sheds Light on the Reasons Behind Sex Differences in Myocarditis

November 3, 2022 — In the past several years, myocarditis has been of public interest because of cases associated with ...

November 03, 2022

Fig. 1. Selective reduction of succinyl-CoA among the TCA cycle metabolites in cardiac muscle during chronic HF. Relative levels of the TCA cycle metabolites in cardiac muscles isolated from myocardial infarction (MI) mice, compared with those from sham mice, 28 d after surgery. Each data point in the dot plot represents one individual mouse sample (n = 38 for both groups for all metabolites, except for succinyl-CoA in which n = 18 for both groups). Concentrations of succinyl-CoA in these samples were 2.2–5

News | Heart Failure

How Heart Failure Disrupts the Cell's Powerhouse

November 3, 2022 — Chronic heart failure causes the cell’s powerhouses to dysfunction, in part due to overconsumption of ...

November 03, 2022

Videos | TCT

VIDEO: Clinical Science in Structural Heart Disease

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

November 03, 2022

After mRNA vaccination, adults under 40 have a slightly greater chance of developing myocarditis or pericarditis, yet the vaccine’s benefits outweigh the risks, according to the American Journal of Preventive Medicine

News | Coronavirus (COVID-19)

Getting to the Heart of COVID-19 Vaccination and its Cardiovascular Risks

November 2, 2022 — A comprehensive review and meta-analysis of published research confirm that young adults (40 years ...

November 02, 2022